Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811295 | 0.82 | HTT (0.47) | BACE1HTTTAS1R3TAS1R1HDAC4 | |
| SCHEMBL4810047 | 0.80 | BACE1 (0.62) | BACE1HTTHDAC4DGAT2CNR1 | |
| SCHEMBL4813230 | 0.79 | BACE1 (0.50) | BACE1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4810071 | 0.78 | BACE1 (0.62) | BACE1SMN1; SMN2 | |
| SCHEMBL4815170 | 0.77 | BACE1 (0.75) | BACE1RAB9A | |
| SCHEMBL4813038 | 0.76 | BACE1 (0.62) | BACE1 | |
| SCHEMBL4806389 | 0.76 | BACE1 (0.75) | BACE1 | |
| SCHEMBL4816021 | 0.71 | BACE1 (0.51) | BACE1KDM4E | |
| SCHEMBL4813819 | 0.69 | BACE1 (0.67) | BACE1HTTNPC1RAB9AKDM4E | |
| SCHEMBL4812986 | 0.69 | BACE1 (0.93) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2006088694-A1 | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | BACE1, BACE2, PSEN1 | BACE1 1/4885HTT 318/4885TAS1R3 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.